不同剂量替罗非班联合冠脉介入术治疗非ST段抬高型急性冠脉综合征患者的临床疗效及安全性

Clinical Curative Effect and Safety of Different Doses of Tirofiban and Percutaneous Coronary Intervention in Treatment of NEST-ACS

目的该次主要对不同剂量替罗非班与冠脉介入术(PCI)治疗非ST段抬高型急性冠脉综合征(NST-ACS)患者的效果与及安全性进行分析。方法方便选取该院2014年10月—2016年10月收治并已确诊的(NST-ACS)患者150例,根据所有患者入院治疗差异平均分为3组,即A组(常规治疗+PCI),B组(在A组治疗基础上给予全量替罗非班),C组(在A组治疗前提下给予半量替罗非班)。对比3组疗效。结果 B组治疗的总疗效100.00%与C组的96.00%高于A组的86.00%,差异有统计学意义(P<0.05),有可比性;但B、C两组对比差异无统计学意义(P>0.05)。结论NST-ACS患者经半量替罗非班结合冠脉介入术治疗的临床效果确切,不仅可提高治疗的效果,还能有效降低心血管事件的发生机率,值得推广。

Objective To analyze the clinical curative effect and safety of different doses of tirofiban and percutaneous coronary intervention in treatment of NEST-ACS. Methods Convenient selection 150 cases of patients with NEST-ACS admitted and treated in our hospital from October 2014 to October 2016 were selected and divided into three groups with 50 cases in each, the group A were treated with routine method and PCI, the group B were treated with full-dose tirofiban on the basis of the group A, the group C wre treated with half-dose tirofiban on the basis of the group A, and the curative effect of the three groups was compared. Results The total curative effect in the group B and the group C was higher than that in the group A（100.00%, 96.00% vs 86.00%）, and the difference had statistical significance（P〈0.05）, and the difference between the group B and the group C had no statistical significance（P〉0.05）. Conclusion The clinical effect of half-dose tiroifban and percutaneous coronary intervention in treatment of NEST-ACS is definite, which can not only improve the treatment effect but also effectively reduce the occurrence probability of cardiovascular events, which is worth promotion.